RxDoctor Payments DataLook up a doctor →

Eric Wolfson, DO

Internal Medicine · Las Vegas, NVNPI 1023044773

Payments from drug & device makers

$18,689in general payments, 2019–2025

Across 521 payments — averaging $35.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dr.reddy's Laboratories,inc.$9K
  • AstraZeneca$2K
  • AbbVie$1K
  • Novo Nordisk$808
  • Astellas Pharma US Inc$710
  • Bayer$502
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$8,87394%
  • Education$5726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Dr.reddy's Laboratories,inc.2$9,244
AstraZeneca65$1,500
AbbVie(2 entities)73$1,038
Novo Nordisk53$808
Astellas Pharma US Inc24$710
Bayer31$502
Amgen(2 entities)19$384
Abbott21$379
Lilly USA, LLC23$336
Dexcom, Inc.16$292
Merck17$284
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$251
Boehringer Ingelheim14$240
Mannkind Corporation11$199
Gilead9$188
Pfizer8$161
E.r. Squibb & Sons, L.L.C.8$155
Exact Sciences8$129
Otsuka America Pharmaceutical, Inc.6$127
Sanofi-aventis U.S. LLC8$122
Novartis6$118
GSK5$100
Almatica Pharma LLC4$77
Eisai Inc.4$73
Baxter Healthcare3$70
Idorsia Pharmaceuticals US Inc4$59
Ascensia Diabetes Care US Inc.4$56
Antares Pharma, Inc.3$49
Endo Pharmaceuticals Inc.2$48
Sumitomo Pharma America, Inc.3$48
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$48
Biohaven Pharmaceuticals, Inc.3$45
Esperion Therapeutics, Inc.2$45
Takeda Pharmaceuticals U.S.A., Inc.2$44
Biohaven Pharmaceutical Holding Company Ltd.3$43
Paratek Pharmaceuticals, Inc.2$43
Shield Therapeutics Inc2$40
Insulet Corporation2$35
Vanda Pharmaceuticals Inc.1$34
Nevro Corp.1$32
Halozyme Inc2$31
Medtronic(2 entities)2$31
Supernus Pharmaceuticals, Inc.2$29
Shire North American Group Inc2$28
Viiv Healthcare Company1$27
Melinta Therapeutics, LLC2$26
Xeris Pharmaceuticals, Inc.1$25
Kowa Pharmaceuticals America, Inc.1$24
Acella Pharmaceuticals, LLC1$23
Optinose US, Inc.1$22
Aimmune Therapeutics, Inc.1$22
Lifescan, Inc.1$21
Intra-sana Laboratories1$19
Boston Scientific1$19
Tolmar, Inc.1$18
Bardy Diagnostics, Inc.1$18
Amarin Pharma, Inc.1$17
UCB, Inc.1$17
Lundbeck LLC1$17
Lucid Diagnostics Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,689 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$229,608
Medicare patients
448
Services billed
2,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol126$172,408
EliquisApixaban97$133,497
OzempicSemaglutide114$121,426
JardianceEmpagliflozin57$84,675
MounjaroTirzepatide50$52,454
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf11$48,656
JanuviaSitagliptin Phosphate30$43,343
XareltoRivaroxaban26$33,562
LinzessLinaclotide38$32,487
DescovyEmtricitabine/Tenofov Alafenam13$27,838
TrulicityDulaglutide18$25,949
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$18,103
RexultiBrexpiprazole12$17,703
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$16,575
Lantus SolostarInsulin Glargine,hum.Rec.Anlog75$15,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,500$197,046170 claims
PfizerEliquis, Prempro$161$139,530115 claims
Novo NordiskOzempic$808$121,426114 claims
Boehringer IngelheimJardiance$240$84,67557 claims
Lilly USA, LLCMounjaro, Trulicity$336$78,40368 claims
MerckJanuvia$284$43,34330 claims
AbbVieLinzess, Synthroid$1,038$34,59456 claims
GSKTrelegy Ellipta, Breo Ellipta$100$29,45833 claims
GileadDescovy$188$27,83813 claims
Otsuka America Pharmaceutical, Inc.Rexulti$127$17,70312 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$44$5,64712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →